ArticleAnnals of surgical oncology2023

CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/Nab-Paclitaxel for Patients with Operable Pancreatic Cancer.

Sam Z Thalji et al.PubMed ↗Publisher ↗

No numbers read from the abstract.